뉴벡티스 파마(NVCT)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $22.00 (+2.90%), 시가총액 $0.29B, 52주 최저~최고 $5.65 ~ $12.45.
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
뉴벡티스 파마의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
뉴벡티스 파마의 현재 주가는 $22.00 (+2.90%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
뉴벡티스 파마의 시가총액은 약 $0.29B입니다.
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The comp